Clinical Trial

Dextenza in the Post-op Management of Vitreoretinal Surgeries

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This study will assess the control of inflammation at days 1, 7, 14, and 21 days following the vitreoretinal surgical procedure analyzing two randomized study arms: Intracanalicular dexamethasone insert group or topical steroid drop group. Patients must be 18 years of age and older, of any race and either sex, requiring surgery with the procedure type of pars plana vitrectomy for either the indication of macular hole, epiretinal membrane removal, or vitreomacular traction.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-05-01 -> 2027-12-01 2026-07-30
minor Completion pushed: 2026-05-01 -> 2027-12-01 2026-07-30
Trial Details
NCT Number NCT04371445
Lead Sponsor The Cleveland Clinic
Collaborators: Ocular Therapeutix, Inc.
Conditions Vitreoretinal Surgery, Ocular Inflammation, Post-operative Pain, Post-Operative Inflammation
Enrollment 30 participants
Start Date 2020-06-01
Primary Completion 2027-12-01 (estimated)
Study Completion 2027-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-29